IRD — Opus Genetics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1228627 ·
Last close
$5.05
Market Cap
$420.14M
52W High
$7.07
52W Low
$1.50
ADV30
3,815,621
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 755,000 | — | -16,480,000 | -8,098,000 | 92,968,000 | 88,812,000 | 105,954,000 |
| Mar 2026 | 2,157,000 | — | -14,364,000 | -65,535,000 | 66,787,000 | 59,959,000 | 112,623,000 |
| Dec 2025 | 3,865,000 | — | -11,453,000 | -16,523,000 | 50,243,000 | 45,091,000 | 34,895,000 |
| Sep 2025 | 3,079,000 | — | -8,311,000 | -17,454,000 | 36,122,000 | 30,815,000 | 30,155,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,667,000
Investing CF
$0
Financing CF
$97,150,000
CapEx
—
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.20
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-262,222,000
Inventory
—
Receivables
$1,456,000
ST Investments
$0
EBIT TTM
$-104,962,000
Pretax Income TTM
$-107,610,000
Interest Exp TTM
$2,648,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,856,000
EBITDA
$-50,555,000
Free Cash Flow
$-38,555,752
Enterprise Value
$449,894,784
Total Cash
$88,812,000
Total Debt
$36,204,000
Shares Out
83,195,823
Trailing EPS
$-1.29
Book Value
$-0.16
ROE
-4796.5%
ROA
-48.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,196,000 | -38,599,000 | -49,591,000 | 50,243,000 | 34,895,000 | 15,348,000 | -35,253,000 |
| Dec 2024 | 10,992,000 | -34,074,000 | -57,532,000 | 36,862,000 | 30,138,000 | 6,724,000 | -25,576,000 |
| Dec 2023 | 19,049,000 | -10,563,000 | -9,986,000 | 53,948,000 | 4,042,000 | 49,906,000 | -1,112,000 |
| Dec 2022 | 39,850,000 | 18,226,000 | 17,888,000 | 48,992,000 | 2,753,000 | 46,239,000 | 14,314,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.71
Max Pain — expiry 2026-11-20
max pain strike: $5.00 · spot: $5.05 · call oi: 3,323 · put oi: 75
Expected Move to 2026-11-20:
±$1.73
(34.16%) —
implied range
$3.33 –
$6.78
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $419.56M | $12.73 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $417.06M | $5.20 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $411.00M | $14.46 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $410.72M | $4.13 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $429.91M | $0.41 | — |
News headlines (Yahoo Finance, 1h cache)
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
2026-09-16 22:17 · Yahoo
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
2026-09-09 17:19 · Yahoo
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027
2026-09-09 14:37 · Yahoo
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
2026-09-09 11:00 · Yahoo
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
2026-09-02 11:00 · Yahoo
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
2026-09-01 12:59 · Yahoo
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 20:01 · Yahoo
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
2026-08-06 11:00 · Yahoo
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
2026-07-09 11:00 · Yahoo
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
2026-06-26 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.